This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, E. M.
Right arrow Articles by Warnock, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, E. M.
Right arrow Articles by Warnock, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1412-1416, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparison of In Vitro Antifungal Activities of Free and Liposome-Encapsulated Nystatin with Those of Four Amphotericin B Formulations

Elizabeth M. Johnson,1 Joshua O. Ojwang,2 Adrien Szekely,1 Thomas L. Wallace,2 and David W. Warnock1,*

Mycology Reference Laboratory, Public Health Laboratory Service, Bristol, United Kingdom,1 and Aronex Pharmaceuticals Inc., The Woodlands, Texas 77381-11912

Received 31 October 1997/Returned for modification 5 January 1998/Accepted 8 April 1998

The in vitro activity of a multilamellar liposomal formulation of nystatin (Nyotran) was compared with those of free nystatin and four pharmaceutical preparations of amphotericin B. MICs for 200 isolates of two Aspergillus spp., seven Candida spp., and Cryptococcus neoformans were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Minimum lethal concentrations (MLCs) of the six antifungal preparations were also determined. Both nystatin formulations possessed fungistatic and fungicidal activities against the 10 species tested. Liposomal nystatin appeared to be as active as free nystatin, with MICs and MLCs that were similar to, or lower than, those of the latter. Neither formulation of nystatin was as active as amphotericin B deoxycholate (Fungizone) or amphotericin B lipid complex (Abelcet), but both were more effective than liposomal amphotericin B (AmBisome). Our results suggest that further evaluation of liposomal nystatin is justified.

* Corresponding author. Mailing address: Mycology Reference Laboratory, Public Health Laboratory, Kingsdown, Bristol BS2 8EL, United Kingdom. Phone: (44) 117-928-5030. Fax: (44) 117-922-6611. E-mail: D.W.Warnock{at}PHLSBristol.btinternet.com.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1412-1416, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Offner, F., Krcmery, V., Boogaerts, M., Doyen, C., Engelhard, D., Ribaud, P., Cordonnier, C., de Pauw, B., Durrant, S., Marie, J.-P., Moreau, P., Guiot, H., Samonis, G., Sylvester, R., Herbrecht, R., the EORTC Invasive Fungal Infections Group, (2004). Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B. Antimicrob. Agents Chemother. 48: 4808-4812 [Abstract] [Full Text]  
  • Pfaller, M. A., Sheehan, D. J., Rex, J. H. (2004). Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization. Clin. Microbiol. Rev. 17: 268-280 [Abstract] [Full Text]  
  • Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y. (2004). Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother 53: 311-317 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Alfaro, R. M., King, C., Piscitelli, S. C., Walsh, T. J. (2003). Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits. Antimicrob. Agents Chemother. 47: 3917-3925 [Abstract] [Full Text]  
  • Kuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., Ghannoum, M. A. (2002). Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins. Antimicrob. Agents Chemother. 46: 1773-1780 [Abstract] [Full Text]  
  • Dannaoui, E., Meis, J. F. G. M., Mouton, J. W., Verweij, P. E., the Eurofung Network, (2002). In vitro susceptibilities of Zygomycota to polyenes. J Antimicrob Chemother 49: 741-744 [Abstract] [Full Text]  
  • Arikan, S., Ostrosky-Zeichner, L., Lozano-Chiu, M., Paetznick, V., Gordon, D., Wallace, T., Rex, J. H. (2002). In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates. J. Clin. Microbiol. 40: 1406-1412 [Abstract] [Full Text]  
  • Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E. (2002). In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrob. Agents Chemother. 46: 62-68 [Abstract] [Full Text]  
  • Warn, P. A., Morrissey, J., Moore, C. B., Denning, D. W. (2000). In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible Candida tropicalis. Antimicrob. Agents Chemother. 44: 2664-2671 [Abstract] [Full Text]  
  • Gunderson, S. M., Hoffman, H., Ernst, E. J., Pfaller, M. A., Klepser, M. E. (2000). In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect. Antimicrob. Agents Chemother. 44: 2887-2890 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Werner, K., Petraitiene, R., Petraitis, V., Calendario, M., Field-Ridley, A., Crisp, J., Piscitelli, S. C., Walsh, T. J. (2000). Compartmental Pharmacokinetics and Tissue Distribution of Multilamellar Liposomal Nystatin in Rabbits. Antimicrob. Agents Chemother. 44: 950-957 [Abstract] [Full Text]  
  • Machard, S., Theodoro, F., Benech, H., Grognet, J.-M., Ezan, E. (2000). A Sensitive Amphotericin B Immunoassay for Pharmacokinetic and Distribution Studies. Antimicrob. Agents Chemother. 44: 546-550 [Abstract] [Full Text]  
  • Larson, J. L., Wallace, T. L., Tyl, R. W., Marr, M. C., Myers, C. B., Cossum, P. A. (2000). The Reproductive and Developmental Toxicity of the Antifungal Drug Nyotran(R) (Liposomal Nystatin) in Rats and Rabbits. Toxicol Sci 53: 421-429 [Abstract] [Full Text]  
  • Carrillo-Munoz, A. J., Quindos, G., Tur, C., Ruesga, M. T., Miranda, Y., Valle, O. d., Cossum, P. A., Wallace, T. L. (1999). In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 44: 397-401 [Abstract] [Full Text]  
  • Oakley, K. L., Moore, C. B., Denning, D. W. (1999). Comparison of In Vitro Activity of Liposomal Nystatin against Aspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole. Antimicrob. Agents Chemother. 43: 1264-1266 [Abstract] [Full Text]  
  • Groll, A. H., Gonzalez, C. E., Giri, N., Kligys, K., Love, W., Peter, J., Feuerstein, E., Bacher, J., Piscitelli, S. C., Walsh, T. J. (1999). Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother 43: 95-103 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»